Previous 10 | Next 10 |
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back ...
Mesoblast CEO & Managing Director Dr Silviu Itescu - The Investor Forum at the World Stem Cell Summit. Each presentation features a formal corporate overview, followed by a Q & A session moderated by a Noble Capital Markets equity research representative. Read More >>
Featuring Avalon GloboCare (AVCO), Caladrius Biosciences (CLBS), Celularity, ImmCelz / Creative Medical Technology Holdings (CELZ), ExoProTher, GID BIO, HealthLynked (HLYK), Longeveron (LGVN), Mesoblast (MESO) - Presented by Channelchek and Noble Capital Markets Read More >>
Investor Forum at the World Stem Cell Summit - June 17, 2021 - presented by Channelchek - Featuring Avalon GloboCare, Caladrius Biosciences, CellZ, Celularity, ExoProTher, GID BIO, Longeveron, Medicinal Cells, Inc., Mesoblast Read More >>
Image source: The Motley Fool. Mesoblast (NASDAQ: MESO) Q3 2021 Earnings Call Jun 02, 2021 , 6:30 p.m. ET Operator Continue reading For further details see: Mesoblast (MESO) Q3 2021 Earnings Call Transcript
Mesoblast (MESO): FQ3 GAAP EPS of -$0.04 misses by $0.11.Revenue of $1.92M (-84.3% Y/Y) vs. a consensus of $46.39M (single analyst).“We are pleased with the recent clinical outcomes regarding our lead product candidate remestemcel-L and continue to progress our regulatory discussions w...
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2021. “We are pleased with ...
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed journal Respiratory Research has published results showing that Mesoblast’s mesenc...
Shares of Mesoblast Limited (NASDAQ: MESO) are rising sharply on Friday after the company reported positive results from a clinical trial for one of its pipeline candidates, remestemcel-L. The biotech's stock was up 7.3% as of 3:22 p.m. EDT, after soaring by as much as 24.5% earlier...
Image Sensing Systems (ISNS) +24% on strategic changes.Motus GI Holdings (MOTS) +47% on FDA 510(k) clearance of Pure-Vu System.Tarena International (TEDU) +10% after entering "going private" merger agreement.Salem Media Group (SALM) +9%.Arcutis Biotherapeutics (ARQT) +8%.Mesobl...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...